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Ibrutinib is an inhibitor of the Tec family kinase, Bruton tyrosine kinase (Btk) approved for the treatment of 
chronic lymphocytic leukemia, mantle cell lymphoma, and 
Waldenstrom macroglobulinemia. Patients receiving ibruti-
nib exhibit deficiencies in hemostasis, resulting in incidents 
of bruising and petechiae in ≤48% of patients and grade 3 
or greater bleeding in 5% of patients.1 Platelets from patients 
receiving ibrutinib exhibit deficient responses to collagen and 
the glycoprotein VI (GPVI)-specific agonist, collagen-related 
peptide (CRP)-XL.2–4 However, responses to other platelet 
agonists such as ADP and U46619 are unaffected or only 
mildly inhibited.2 Btk is a critical component of the signaling 
pathway of the GPVI collagen receptor and ibrutinib seems 
to inhibit collagen-evoked signaling via inhibition of Btk.4 
However, the effects of ibrutinib have predominantly been 
investigated using platelet suspension assays, whereas the 
impact of ibrutinib on adhesion and signaling on immobilized 
ligands has not been explored but may be more representative 
of the platelet environment in vivo. The distinction between 
suspension and adhesion may be critical to understanding the 
underlying mechanism of hemostatic dysfunction caused by 
ibrutinib.
The involvement of Btk in GPVI-evoked platelet signaling 
was first identified when patients having X-linked agamma-
globulinemia, caused by a deficiency in Btk, were found to 
have platelets with impaired responses to collagen.5 However, 
the contribution of Btk to the GPVI signaling pathway is 
partially redundant to the closely related kinase, Tec as only 
simultaneous knockout of both Tec and Btk renders mouse 
platelets insensitive to CRP-XL.6 X-linked agammaglobu-
linemia patients do not exhibit a platelet-dependent bleed-
ing phenotype, which contrasts with the enhanced bleeding 
risk among patients receiving ibrutinib and suggests that Tec 
may also be inhibited by clinically relevant concentrations of 
Ibrutinib. After activation of the platelet GPVI receptor, Btk 
and Tec are activated downstream of Syk, Fyn, and Lyn and 
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Objective—Ibrutinib is an irreversible Bruton tyrosine kinase inhibitor approved for treatment of Waldenstrom 
macroglobulinemia, chronic lymphocytic leukemia, and mantle cell lymphoma that increases the risk of bleeding among 
patients. Platelets from ibrutinib-treated patients exhibit deficiencies in collagen-evoked signaling in suspension; however, 
the significance of this observation and how it relates to bleeding risk is unclear, as platelets encounter immobile collagen 
in vivo. We sought to clarify the effects of ibrutinib on platelet function to better understand the mechanism underlying 
bleeding risk.
Approach and Results—By comparing signaling in suspension and during adhesion to immobilized ligands, we found that 
the collagen signaling deficiency caused by ibrutinib is milder during adhesion to immobilized collagen. We also found 
that platelets in whole blood treated with ibrutinib adhered to collagen under arterial shear but formed unstable thrombi, 
suggesting that the collagen signaling deficiency caused by ibrutinib may not be the predominant cause of bleeding in 
vivo. However, clot retraction and signaling evoked by platelet adhesion to immobilized fibrinogen were also inhibited by 
ibrutinib, indicating that integrin αIIbβ3 outside-in signaling is also effected in addition to GPVI signaling. When ibrutinib 
was combined with the P2Y12 inhibitor, cangrelor, thrombus formation under arterial shear was inhibited additively.
Conclusions—These findings suggest that (1) ibrutinib causes GPVI and integrin αIIbβ3 platelet signaling deficiencies that 
result in formation of unstable thrombi and may contribute toward bleeding observed in vivo and (2) combining ibrutinib 
with P2Y12 antagonists, which also inhibit thrombus stability, may have a detrimental effect on hemostasis.  (Arterioscler 
Thromb Vasc Biol. 2015;35:2326-2335. DOI: 10.1161/ATVBAHA.115.306130.)
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regulate phospholipase Cγ2 (PLCγ2) activation, and thereby 
Ca2+ release and protein kinase C (PKC) activation, which are 
critical events in platelet activation.6,7 In addition to GPVI, 
platelets also express α2β1 and the glycoprotein Ib (GPIb) 
receptor complex that can mediate adhesion to collagen and 
generate intracellular signaling that supports hemostatic plate-
let function.8 Btk has an established role in the signaling path-
way evoked by GPIb9 and consequent inhibition of adhesion 
to Von Willebrand factor (vWF) in the presence of ibrutinib 
has been reported.4 The role of Btk in α2β1-mediated signaling 
is less clear, as is the ability for α2β1 to function in the absence 
of signaling evoked by GPVI,8 making the effects of ibrutinib 
on collagen-evoked adhesion and signaling under shear dif-
ficult to predict.
The role of Btk may not be limited to collagen and vWF-
evoked pathways, as integrin αIIbβ3-evoked outside-in signal-
ing is thought to share many features of the GPVI signaling 
pathway, although conflicting reports about the involvement 
of Btk in outside-in signaling have been published. A study 
reporting that phosphorylation of Btk occurs after direct acti-
vation of integrin αIIbβ3 with MnCl2 in mouse and human 
platelets suggests the involvement of Btk in outside-in signal-
ing.10 However, it has also been reported that mouse platelets 
with simultaneous deficiency of both Btk and Tec adhere and 
spread normally on fibrinogen.6 Overall, the role of Btk in 
integrin αIIbβ3 outside-in signaling is unclear. The effect of 
Ibrutinib on integrin outside-in signaling has not previously 
been explored but offers an opportunity to investigate the role 
of Tec family kinases in such signaling in human platelets. It 
is possible that inhibition of integrin αIIbβ3 outside-in signal-
ing may play a role in bleeding risk as mice with genetically 
modified β3, harboring tyrosine substitutions in the cytoplas-
mic tale that ablate outside-in signaling, have a mild bleeding 
phenotype characterized by poor clot stability that results in 
rebleeding.11
To improve understanding of the effects of ibrutinib on 
platelet function, we performed a comparison of the effects of 
ibrutinib on platelet signaling in suspension and during adhe-
sion to immobilized ligands. Using this strategy, we identified 
key differences that suggested that the previously reported loss 
of platelet collagen sensitivity may not cause a deficiency in 
adhesion to immobile collagen. Further investigation revealed 
that initial adhesion to collagen under arterial shear was not 
inhibited by ibrutinib; however, ibrutinib caused instability 
and disaggregation of thrombi. This lead us to investigate 
positive feedback signaling that supports thrombus stability 
and the subsequent finding that ibrutinib causes inhibition of 
outside-in signaling evoked by integrin αIIbβ3. Because of the 
important role of integrin αIIbβ3 outside-in signaling in clot 
stabilization, inhibition of this pathway in addition to GPVI 
signaling may be an important factor in the bleeding caused 
by ibrutinib.
Materials and Methods
Materials and Methods are available in the online-only Data 
Supplement.
Results
Ibrutinib Inhibits CRP and Collagen-Evoked 
[Ca2+]i Elevation and Aggregation in Suspension
Platelet function has been measured in blood taken from 
patients receiving 560 mg of ibrutinib daily and responses 
to collagen and CRP were found to be inhibited; however, 
the effect of ibrutinib on platelet signaling and adhesion to 
immobile collagen has not been measured.3,4 To provide a 
comparison of the effects of ibrutinib on platelet signaling 
in suspension and during adhesion we first investigated the 
effects of ibrutinib on elevation of [Ca2+]i and aggregation in 
evoked by collagen, CRP-XL, ADP, and U46619 in suspen-
sion. At concentrations of ≤1 µmol/L, ibrutinib inhibited Ca2+ 
elevation evoked by collagen and the GPVI agonist, CRP-XL 
but not ADP or U46619 (Figure 1A). Aggregation evoked by 
collagen or CRP-XL was completely inhibited by 1-µmol/L 
ibrutinib (Figure 1B). However, aggregation evoked by ADP 
was only mildly inhibited (12.7±5.5% inhibition) and the 
kinetics of U46619-evoked aggregation was often slowed 
and appeared biphasic although the trend did not reach sta-
tistical significance at 5 minutes (Figure 1B). The lack of 
Nonstandard Abbreviations and Acronyms
Btk Bruton tyrosine kinase
CRP collagen-related peptide
vWF Von Willebrand factor
Figure 1. Ibrutinib inhibits Ca2+ elevation and aggregation evoked 
by collagen-related peptide (CRP)-XL and collagen. For [Ca2+]i, 
measurements and aggregometry washed platelets (loaded with 
fura-2 for [Ca2+]i measurements) were pretreated with 1-µmol/L 
ibrutinib or vehicle for 5 minutes and stimulated with 1-µg/mL 
type I collagen, 1-µg/mL CRP-XL, 10-µmol/L ADP, or 1-µmol/L 
U46619. Ai, Representative [Ca2+]i traces and (Aii) mean peak 
[Ca2+]i increases normalized to % of vehicle response±SEM (n=4). 
Bi, Representative aggregation traces and (Bii) mean light trans-
mission 5 minutes after addition of agonist±SEM (n=4). *P<0.05, 
****P<0.0001 using 1-way ANOVA with a Bonferroni post test.
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effect of ibrutinib on ADP and U46619-evoked [Ca2+]i eleva-
tion suggests that the observed trend toward mild inhibition 
of aggregation, which has also been noted in other studies,2,4 
may indicate inhibition of positive feedback signaling, such as 
integrin αIIbβ3 outside-in signaling.
Inhibition of GPVI-Evoked Signaling Caused by 
Ibrutinib Is Concentration-Dependent Within the 
Range of Clinically Relevant Concentrations
We used [Ca2+]i quantification and plate-based aggregometry 
to define the concentration dependency of platelet inhibition 
caused by ibrutinib (Figure 2). Ibrutinib inhibited [Ca2+]i ele-
vation evoked by 1 µg/mL CRP-XL with an IC50 of 51 nmol/
L±10.7, whereas half-maximal inhibition of aggregation was 
only achieved at 186 nmol/L±81.2 (Figure 2A and 2B). We 
found that the concentration-dependent component of the 
inhibition curves covered the range of peak serum concentra-
tions measured clinically in patients receiving 560 mg ibruti-
nib daily (mean, 300 nmol/L).12 This suggests that variability 
in plasma concentration may cause large differences in plate-
let inhibition among patients.
Ibrutinib is an irreversible inhibitor of Btk,13 and therefore, 
expected to exhibit insurmountable inhibition with limited or 
no dependence on stimulus strength. However, a positive cor-
relation between log[CRP-XL] and logIC50 was identified, 
and may be indicative of ibrutinib interacting with >1 target 
with different affinities (Figure 2C and 2D). It is tempting to 
speculate that these targets may represent the 2 Tec family 
kinases expressed by platelets, Btk and Tec, both of which are 
inhibited by ibrutinib.13 However, we were unable to blot to 
determine the relative phosphorylation of these 2 Tec family 
kinases to investigate this further.
Ibrutinib Inhibits Signaling Evoked 
by GPVI Downstream of PLCγ2
Ibrutinib is an inhibitor of other kinases in addition to Btk, 
including Src family kinases and Tec,13 which could contrib-
ute toward the observed platelet inhibition. Although ibrutinib 
has been screened for activity against a panel of kinases, the 
screen was performed in a cell-free in vitro assay and the esti-
mated IC50 values do not seem to correlate closely with the 
potency of ibrutinib observed in vivo or ex vivo. We found that 
ibrutinib inhibits Src phosphorylation at Y418 with an IC50 
of 2.0 µmol/L±1.05 (Figure 3A and 3B), which was 20-fold 
higher than that required for half-maximal inhibition of [Ca2+]i 
elevation (IC50=51 nmol/L±10.7) evoked by the same concen-
tration of CRP-XL (Figure 2A). Phosphorylation of Syk was 
not inhibited by 1-µmol/L ibrutinib, (174%±54 relative to 
control; Figure 3D) a concentration that ablated both [Ca2+]i 
elevation and aggregation evoked by 1 µg/mL CRP-XL. Taken 
together, these observations suggest that the potent inhibition 
of GPVI signaling caused by ibrutinib is not attributable to 
inhibition of Src family kinases. In contrast to measurements 
of Src and Syk phosphorylation, 1-µmol/L ibrutinib was found 
to ablate PLCγ2 tyrosine phosphorylation as well as total ser/
thr phosphorylation of all substrates of PKC (Figure 3E and 
3F). Measurement of p-selectin exposure and fibrinogen bind-
ing that are representative of the downstream signaling events 
of granule secretion and integrin αIIbβ3 activation were also 
inhibited by 1-µmol/L ibrutinib (Figure 3G). Btk/Tec forms 
part of the PLCγ2 activation complex down stream of GPVI 
and, therefore, inhibition of PLCγ2, PKC, and [Ca2+]i eleva-
tion are consistent with a Btk/Tec-dependent mode of action. 
To investigate the effects of ibrutinib in subsequent experi-
ments, a concentration of 1 µmol/L was used to ensure that 
complete inhibition of platelet function mediated by GPVI 
was achieved.
Ca2+ Signaling Evoked by Adhesion to Immobilized 
Collagen Is Only Partially Inhibited by Ibrutinib
To understand the significance of the collagen and CRP-
XL-specific inhibition caused by ibrutinib in suspension, 
we studied the effects of ibrutinib on platelet function dur-
ing adhesion to immobilized ligands. Platelet adhesion and 
activation on immobilized collagen is thought to be orches-
trated by GPVI, which triggers activation, integrin α2β1 that 
supports adhesion, and GPIb, which via the interaction with 
vWF ensures initial adhesion to collagen under arterial shear.8 
Although GPVI has the most established role in mediating 
Figure 2. Ibrutinib inhibits GPVI-evoked signaling with potency 
that is partially dependent on stimulus strength. [Ca2+]i measure-
ments and aggregations were performed using washed plate-
lets (loaded with fura-2 for [Ca2+]i measurements) pretreated 
for 5 minutes with ibrutinib at the indicated concentrations and 
stimulated with a range of collagen-related peptide (CRP)-XL 
concentrations between 10 and 10 ng/mL CRP-XL or vehicle 
only. Average concentration responses (A) expressed as the 
peak increase in [Ca2+]i or (B) % light transmission after 5 minutes 
of platelet aggregation are mean±SEM (n=4). The relationship 
between the stimulating (CRP-XL) and apparent IC50 of ibruti-
nib in Ca2+ (C) and aggregation (D) assays are derived from the 
curves presented in (A) and (B), respectively and are mean±SEM 
(n=4). Correlation between the apparent IC50 of ibrutinib and 
CRP-XL concentration was tested using Pearson correlation 
test and found to be significant (P<0.05) for both [Ca2+]i increase 
(r=0.93) and aggregation (r=0.97).
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collagen-evoked intracellular signaling, integrin α2β114 may 
also be capable of initiating signaling. The effects of ibru-
tinib on adhesion to immobile collagen were, therefore, dif-
ficult to predict, but may be significant in understanding the 
mechanism, by which it causes bleeding. We found that adhe-
sion of platelets to immobilized CRP-XL was inhibited by 
70%±13.9 in the presence of 1-µmol/L ibrutinib (Figure 4Ai 
and 4Aii). Spreading under these conditions was also 
strongly inhibited where the proportion of platelets exhibit-
ing lamellipodia was reduced from 69%±5.3 to 11%±4.8 in 
the presence of 1-µmol/L ibrutinib (Figure 4Aiii). The effi-
cacy of ibrutinib as an inhibitor of platelet function mediated 
by GPVI, therefore, seemed to be maintained in spreading 
experiments. Adhesion to CRP-XL seemed to be dependent 
on activation, which was blocked by ibrutinib. CRP-XL is 
not an adhesive ligand and adhesion to CRP-XL may be, 
therefore, reliant on deposition of adhesive proteins present 
in α-granules, such as vWF and fibrinogen that are secreted 
on activation.15 In contrast, adhesion to type I collagen was 
not significantly inhibited by the presence of 1-µmol/L ibru-
tinib relative to control (100%±2.5; Figure 4Aii). Spreading 
and formation of lamellipodia on collagen was significantly 
inhibited in the presence of ibrutinib (48%±8.9 express-
ing lamellipodia in the presence of vehicle compared with 
Figure 3. Inhibition of GPVI-evoked signaling occurs at the level of phospholipase Cγ2 (PLCγ2) activation. A, Washed platelets were 
pretreated for 5 minutes with a range of concentrations of ibrutinib or vehicle before stimulation with 1 µg/mL collagen-related peptide 
(CRP)-XL for 1 minute before immunoblotting for Src Y418. B, The mean relative phosphorylation levels of Src Y418±SEM (normalized 
to total Src; n=4). C, Washed platelets were pretreated for 5 minutes with 1-µmol/L ibrutinib or vehicle before stimulation with 1-µg/mL 
CRP-XL for 1 minute, samples were blotted for Ser/Thr phosphorylation of protein kinase C (PKC) substrates or used for immunoprecipi-
tation of Syk or PLCγ2 and blotted for tyrosine phosphorylation (using 4G10 antibody). Bar charts are mean normalized phosphorylation 
values±SEM for (D) tyrosine phosphorylation of Syk normalized to total Syk (E) tyrosine phosphorylation PLCγ2 relative to total PLCγ2 
and (F) total serine/threonine phosphorylation of substrates of PKC relative to actin (n=3). G, Flow cytometry measurements of fibrinogen 
binding and p-selectin exposure after treatment of platelets for minutes with 1-µg/mL CRP-XL in the presence or absence of 1-µmol/L 
ibrutinib (n=4). *P<0.05, **P<0.01, ***P<0.001 using 1-way ANOVA with a Bonferroni post test.
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33%±6.6 with 1-µmol/L ibrutinib) but to a lesser extent than 
on CRP-XL (Figure 4Aiii). The differential effects of ibru-
tinib on adhesion and spreading on immobilized collagen 
and CRP-XL suggest that Btk-independent signaling may be 
stimulated by adhesion to collagen.
To explore the apparent differences in the effects of ibru-
tinib during stimulation with immobilized or solubilized col-
lagen, we investigated signaling evoked by adhesion to type 
I collagen. Ibrutinib reduced PLCγ2 phosphorylation by 
84% relative to control, whereas it was ablated by dasatinib 
Figure 4. Signaling and adhesion evoked by immobilized collagen is only partially inhibited by ibrutinib and ablated by dasatinib. Ai, 
Washed platelets were pretreated for 5 minutes with 1-µmol/L ibrutinib or vehicle and allowed to adhere to type I collagen or collagen-
related peptide (CRP)-coated cover glass for 45 minutes. Aii, The relative percentage of adhered platelets relative to vehicle treated 
(Aiii) and the percentage of platelets that had formed lamellapodia were quantified as mean %±SEM (n=5). Bi, Washed platelets were 
pretreated for 5 minutes with 1-µmol/L ibrutinib or vehicle and allowed to adhere to type I collagen-coated plates for 30 minutes before 
platelets were lysed and probed for phospholipase Cγ2 (PLCγ2) phosphorylation and phosphorylation of protein kinase C (PKC) sub-
strates. Bar charts are mean normalized phosphorylation values±SEM for (Bii) tyrosine phosphorylation of PLCγ2 relative to total PLCγ2 
and (Biii) serine/threonine phosphorylation of substrates of PKC relative to actin. (n=5). C, Platelet rich plasma was loaded with fluo-4 
AM and imaged at 1 Hz during adhesion and spreading on type I collagen-coated cover glass under static conditions for 15 minutes 
in the presence of 1-µmol/L ibrutinib, 1-µmol/L dasatinib or vehicle only. Ci, The traces are fluorescence intensity plots representative 
of between 10 and 60 adhered platelets measured in each of 3 different donors, (Cii) bar charts are mean area under the curve (AUC) 
measurements±SEM (n=3). *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001 using 1-way ANOVA with a Bonferroni post test.
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(Figure 4B), a kinase inhibitor that targets Src family kinases 
and causing platelet inhibition and bleeding side effects in 
patients.16 Total ser/thr phosphorylation of all PKC substrates, 
which lie downstream of PLCγ2 were also partially inhibited 
by ibrutinib (76%±9.8 relative to control) and strongly inhib-
ited by dasatinib (5%±0.6 relative to control). We used single-
cell imaging to measure [Ca2+]i in individual platelets as they 
came into contact with type I collagen-coated cover glass in 
the presence or absence of ibrutinib or dasatinib. Unlike the 
complete ablation observed when platelets were stimulated 
with collagen in suspension (Figure 1A), [Ca2+]i elevation was 
only partially inhibited by ibrutinib during adhesion to immo-
bilized collagen (50%±8.1 of vehicle response; Figure 4Cii). 
In the presence of ibrutinib, the sustained [Ca2+]i elevation 
evoked by collagen in the majority of platelets was replaced 
by ragged [Ca2+]i spiking (Movie I in the online-only Data 
Supplement) more commonly associated with weaker ago-
nists, such as ADP (Figure 4Ci).17 In contrast, the Src fam-
ily kinase inhibitor dasatinib caused complete inhibition of 
[Ca2+]i elevation evoked by immobilized collagen (9%±8.7 of 
vehicle response; Figure 4Cii). Taken together, this suggests 
that signaling stimulated by adhesion to collagen is not 
potently inhibited by ibrutinib. This contrasts directly with the 
total inhibition caused by ibrutinib after stimulation with col-
lagen in suspension observed in this study (Figures 1 and 2) 
and in other studies.3,4 We suggest that signaling initiated by 
adhesion to collagen differs fundamentally to that in suspen-
sion and the role of Btk and the effects of ibrutinib also differ 
under these conditions.
Platelets Adhere to Collagen But Do Not 
Form Stable Thrombi Under Arterial 
Shear After Treatment With Ibrutinib
Because we had identified key differences between the 
effects of ibrutinib on platelet function in suspension and 
during adhesion to immobilized collagen, we investigated 
further using an in vitro thrombus formation assay to assess 
whether the remaining collagen-mediated signaling of ibru-
tinib-treated whole blood could support thrombus formation 
on type I collagen under arterial shear conditions. After treat-
ment with 1-µmol/L ibrutinib levels of thrombus formation 
after 10 minutes were significantly inhibited relative to control 
Figure 5. Ibrutinib inhibits stable thrombus formation but not adhesion to immobilized collagen. A, Thrombus formation was measured 
using whole blood in preincubated for 5 minutes with vehicle, 1-μmol/L ibrutinib or 1-μmol/L cangrlor or both before perfusion through a 
type I collagen-coated channel for 8 minutes. Images are representative fluorescence intensity plots after 7 minutes and traces are (Bi) 
mean fluorescence intensity of thrombi with (Bii) bar charts of mean fluorescence intensity±SEM after 10 minutes and (Ci) traces of mean 
surface coverage with (Cii) bar charts of mean surface coverage±SEM after 10 minutes (n=4). **P<0.01, ***P>0.001, ****P<0.0001 using 
1-way ANOVA with a Bonferroni post test.
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(39%±9.2 of vehicle-treated controls; Figure 5Bi and 5Bii). 
However, surface coverage was not significantly reduced by 
ibrutinib (96%±12.2 of vehicle-treated controls; Figure 5C). 
This suggests that although collagen-evoked signaling via 
GPVI is effectively ablated by this concentration of ibrutinib 
in other assays, the remaining signaling evoked by collagen is 
sufficient to support adhesion. Despite this, thrombus stability 
appeared to be affected by ibrutinib resulting in disaggregation 
of growing thrombi after initial stable adhesion of platelets 
to collagen (Movie II in the online-only Data Supplement). 
To test whether ibrutinib might be inhibiting secretion of sec-
ondary mediators such as ADP, the P2Y12 inhibitor cangrelor 
was tested alone and in combination with the same thrombus 
formation assay. When platelets were treated with 1-µmol/L 
cangrelor, thrombus formation was inhibited (51%±12.9 of 
vehicle-treated controls; Figure 5B), whereas surface coverage 
was not (113%±19.6 of vehicle-treated controls; Figure 5C). 
Similar to the effect of ibrutinib, cangrelor did not affect ini-
tial adhesion to collagen but did inhibit stable thrombus for-
mation. However, although cangrelor treatment resulted in 
embolization of clumps of platelets from growing thrombi, 
ibrutinib caused disaggregation of individual platelets (Movie 
II in the online-only Data Supplement). When ibrutinib and 
cangrelor treatments were combined, thrombus formation was 
more strongly inhibited (24%±6.0 of vehicle-treated controls; 
Figure 5B) than by cangrelor treatment alone (although the 
difference was only significant at intermediate time points, 
1-way ANOVA with Bonferroni post test; P<0.05 after 7 min-
utes), whereas surface coverage was not significantly reduced 
(79% 18.9 of vehicle-treated controls; Figure 5C). These find-
ings suggested that stimulation of P2Y12 by secreted ADP was 
still occurring in the presence of ibrutinib and that blockade 
using cangrelor resulted in further inhibition of thrombus sta-
bility. The comparison with cangrelor also highlighted that 
the effects of the 2 inhibitors were similar and both caused 
decreased thrombus stability rather than a defect in initial 
adhesion to collagen.
Ibrutinib Inhibits Outside-In Signaling 
Mediated by Integrin αIIbβ3
It has already been established that ibrutinib does not inhibit 
signaling evoked by secreted secondary mediators that sup-
port thrombus growth and stability, therefore, to explore the 
unexplained effects of ibrutinib on thrombus stability, we 
investigated integrin αIIbβ3 outside-in signaling. Binding of 
fibrinogen to integrin αIIbβ3 evokes outside-in signaling that 
supports adhesion and spreading on immobilized fibrinogen. 
The physiological role of outside-in signaling is to provide 
positive feedback for platelet-activating stimuli and support 
clot retraction. We investigated outside-in signaling evoked 
during adhesion and spreading on immobilized fibrinogen to 
explore whether the inhibitory mechanism of ibrutinib lies 
in the disruption of the outside-in signaling pathway, which 
has been reported to involve Btk.10 Phosphorylation of β3 
Y773 (83%±14.26), one of the critical tyrosine residues in 
the human β3 cytoplasmic domain for initiation of outside-in 
signaling,11 and Src Y418 (77%±20.3) were not significantly 
altered relative to vehicle-treated control after adhesion to 
fibrinogen in the presence of 1-µmol/L ibrutinib (Figure 6A). 
This suggested that early stages in the outside-in signaling 
pathway are unaffected by ibrutinib. We measured Ca2+ sig-
naling evoked by integrin αIIbβ3 using live imaging of intracel-
lular fluo-4 in individual platelets adhering to and spreading 
on fibrinogen (Movie III in the online-only Data Supplement). 
The sustained [Ca2+]i oscillations observed in the majority of 
adhered platelets was strongly inhibited by 1-µmol/L ibrutinib 
resulting in significantly lower area under the curve measure-
ments relative to control (Figure 6B). We also measured adhe-
sion and spreading of platelets on fibrinogen-coated cover 
glass and found that adhesion was inhibited by 48%±5.4 in the 
presence of 1-µmol/L ibrutinib and the proportion of platelets 
forming lamellipodia was reduced (36%±5.6 compared with 
79%±8.9 in the presence of vehicle; Figure 6C). Finally, ibru-
tinib also inhibited the process of thrombin-stimulated clot 
retraction, which is stimulated by integrin αIIbβ3 outside-in 
signaling, by 110%±32.4 (relative to vehicle-treated mean clot 
weight measured after 2 hours; Figure 6D). Taken together, 
these experiments provide evidence that ibrutinib affects out-
side-in signaling evoked by integrin αIIbβ3 resulting in inhibi-
tion of [Ca2+]i elevation and the processes of platelet spreading 
and clot retraction.
Discussion
Pharmacological inhibition of the kinase, Btk, has proven to 
be a successful therapeutic strategy for the treatment of B-cell 
based cancers and the irreversible Btk inhibitor ibrutinib has 
been approved by the Food and Drug Administration to treat 
mantle cell lymphoma, chronic lymphocytic leukemia, and 
Waldenstrom macroglobulinemia. However, ibrutinib treat-
ment is associated with increased risk of bleeding among 
patients. Until this study, the effects of ibrutinib on platelet 
function have predominantly been investigated using aggre-
gation assays and other techniques performed in suspension. 
Aggregation assays constitute a critical clinical and diagnostic 
tool that aid investigation of platelet-based bleeding disorders. 
However, aggregometry has limited use in that it does not 
replicate platelet thrombus formation on immobile surfaces 
in vivo. Adhesion-based platelet function assays such as the 
PFA-100 are frequently used, but have limited sensitivity18 
and consequently more sophisticated in vitro thrombus forma-
tion assays have been developed to enhance diagnosis of plate-
let disorders.19 In this study, the effects of ibrutinib in assays 
performed in suspension and during adhesion to immobilized 
collagen were compared to provide a better understanding of 
how ibrutinib causes platelet signaling deficiencies and how 
these may affect hemostasis.
The bleeding associated with ibrutinib has been corre-
lated with its inhibitory effects on collagen-mediated plate-
let aggregation.2–4 We found that although ibrutinib caused 
potent inhibition of aggregation and [Ca2+]i elevation in 
suspension, that even at a concentration (1 µmol/L) that 
exceeds plasma concentrations measured clinically, ibrutinib 
did not completely inhibit adhesion to or signaling evoked 
by immobilized collagen. Although PLCγ2 activation in the 
presence of ibrutinib was markedly reduced, Ca2+ signaling 
and PKC substrate phosphorylation was less strongly inhib-
ited. This may be indicative of signal amplification mediated 
by secretion of secondary mediators that act via PLCβ to 
D
ow
nloaded from
 http://ahajournals.org by on April 4, 2019
Bye et al    Ibrutinib Causes Unstable Thrombus Formation  2333
Figure 6. Signaling and adhesion mediated by integrin αIIbβ3 and clot retraction are inhibited by ibrutinib. Ai, Washed platelets were pre-
treated for 5 minutes with 1-µmol/L ibrutinib or vehicle and allowed to adhere to fibrinogen-coated plates for 30 minutes before platelets 
were lysed and probed for β3 Y773 and Src Y418 phosphorylation. Aii, Bar charts are mean normalized phosphorylation values for β3 
Y773 (relative to total β3) and Src Y418 (relative to 14-3-3)±SEM (n=3). B, Platelet rich plasma (PRP) was loaded with fluo-4 AM and 
imaged at 1 Hz during adhesion and spreading on fibrinogen-coated cover glass under static conditions for 25 minutes in the presence 
of 1-µmol/L ibrutinib or vehicle only. Bi, The traces are fluorescence intensity plots representative of 10 to 60 adhered platelets measured 
in each of 3 donors. Bii, Bar charts are mean area under the curve (AUC) measurements±SEM. Ci, Washed platelets were pretreated 
for 5 minutes with 1-µmol/L ibrutinib or vehicle as indicated in the Figure and allowed to adhere to fibrinogen-coated cover glass for 45 
minutes. Cii, The relative percentage of adhered platelets relative to vehicle treated and (Ciii) the percentage of platelets that had formed 
lamellipodia were quantified as mean %±SEM (n=5). Di, A representative image of clot retraction assessed using PRP treated with vehicle 
or 1-µmol/L ibrutinib 2 hours after addition of 1-U/mL thrombin, (Dii) bars represent mean clot weight±SEM (n=6). *P<0.05, ***P<0.001, 
****P<0.0001 using 1-way ANOVA with a Bonferroni post test.
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activate PKC and release Ca2+. Furthermore, initial adhesion 
to collagen under arterial shear stress was not significantly 
inhibited by ibrutinib, whereas stable thrombus formation 
was strongly inhibited. This unexpected finding suggested 
that the mechanism underlying platelet dysfunction caused 
by ibrutinib might involve multiple signaling pathways. We 
and others2–4 have demonstrated that signaling evoked by sec-
ondary mediators is largely unaffected by ibrutinib, and we 
found that signaling via the ADP receptor, P2Y12 still occurs 
in the presence of 1-µmol/L ibrutinib. We therefore looked to 
other sources of positive feedback signaling that contribute 
toward stable thrombus formation and found that outside-in 
signaling evoked by integrin αIIbβ3 was inhibited by ibruti-
nib. Ibrutinib inhibited integrin αIIbβ3 outside-in signaling via 
a similar mechanism to GPVI signaling where it prevented 
PLCγ2 activation and Ca2+ elevation. This is consistent with 
studies that have shown that Btk is activated downstream 
of αIIbβ3 after direct activation with MnCl2.10 Initial events 
in the outside-in signaling cascade such as phosphoryla-
tion of β3 (Y773) and Src were not significantly inhibited 
by ibrutinib suggesting they lie upstream of PLCγ2 acti-
vation when platelets are activated by contact with immo-
bile fibrinogen. In a study that used a mouse model lacking 
integrin αIIbβ3 outside-in signaling because of substitution 
of critical tyrosine residues in the β3 cytoplasmic tail, the 
outside-in signaling deficiency was found to cause rebleed-
ing in tail bleed experiments.11 It is possible that inhibition 
of integrin αIIbβ3 outside-in signaling mediated by ibrutinib 
has similar effects in patients and, therefore, may have a role 
in causing bleeding. Interestingly, the effects of ibrutinib on 
thrombus formation under arterial shear were similar to the 
inhibition caused by cangrelor, which caused embolization 
of thrombi. However, ibrutinib seemed to cause disaggrega-
tion of individual platelets from growing thrombi rather than 
embolization and inhibited thrombus stability additively with 
cangrelor, suggesting that the effects were mediated via dis-
tinct mechanisms.
We suggest that ibrutinib causes a combination of platelet 
function defects via inhibition of Btk and Tec, and we support 
this hypothesis, which is found by comparing the bleeding 
phenotype of patients receiving ibrutinib with that of patients 
with disorders affecting Btk or GPVI function. Patients hav-
ing the Btk deficiency disorder, X-linked agammaglobulin-
emia are not at increased risk of bleeding because platelet Tec 
expression, which is unaffected, contributes signaling that 
overlaps that of Btk.6,20 Ibrutinib inhibits Tec in addition to 
Btk but with lower potency13 and this may explain the dif-
ference in bleeding phenotype between X-linked agamma-
globulinemia patients and patients treated with ibrutinib. We 
found evidence that ibrutinib inhibits at least 2 targets with 
distinct potencies downstream of GPVI that may represent the 
2 Tec family kinases expressed by platelets. Despite strong 
evidence that ibrutinib causes a GPVI-specific platelet signal-
ing defect, bleeding observed in patients does not correlate 
wholly with the reported bleeding phenotype of individuals 
lacking functional GPVI. Although patients with GPVI sig-
naling deficiencies frequently present with petechiae,21 which 
is also observed in patients receiving ibrutinib, lack of GPVI 
function is normally associated with only a mild bleeding 
defect.22–24 Interestingly, platelets with dysfunctional GPVI 
often display markedly impaired adhesion to immobilized col-
lagen,21 whereas this was not the case after ibrutinib treatment 
in this study. This suggests that components of the GPVI sig-
naling pathway that are not dependent on Btk may be able to 
contribute toward adhesion to immobilized collagen via syn-
ergy with signaling evoked by secondary mediators or other 
adhesive receptors.
The mechanism underlying adhesion, secretion of sec-
ondary mediators, and thrombus formation on immobi-
lized collagen in the presence of ibrutinib is unclear given 
the critical role of GPVI-evoked signaling in this process. 
Multiple platelet membrane proteins underlie adhesion and 
signaling in response to collagen. The major role of GPVI 
lies in initiating intracellular signaling, whereas GPIb and 
integrin αIIbβ3 mediate adhesion to collagen via vWF. The 
integrin α2β1 mediates adhesion directly to collagen and is 
thought to be capable of initiating intracellular signaling, 
although evidence also exists that the affinity for collagen 
must first be enhanced via intracellular signaling mediated 
by another receptor.25 The contribution of α2β1 to collagen-
evoked platelet activation is only apparent during adhesion to 
immobilized collagen and not in suspension either in vitro14 
or in vivo after injection of mice with soluble collagen.26 This 
correlates with the observed effect of ibrutinib, which inhib-
its collagen-mediated platelet signaling and aggregation in 
suspension but only partially inhibits signaling and thrombus 
formation on immobilized collagen. However, further inves-
tigation is required to identify the collagen receptor capable 
of initiating signaling in response to collagen in the presence 
of ibrutinib.
Our study has demonstrated that platelet aggregometry 
does not provide an accurate means of identifying the nature 
of platelet function deficiency caused by some drugs, such as 
ibrutinib, because of the critical differences between the con-
tribution of some signaling pathways in suspension and during 
adhesion to immobilized substrates. By using techniques that 
enabled us to study platelet function during adhesion, we came 
to the conclusion that ibrutinib causes a combination of plate-
let functional defects, which result in unstable thrombus for-
mation in vitro and may cause bleeding in vivo. The inhibition 
of GPVI-evoked signaling caused by ibrutinib does not ablate 
collagen-evoked signaling or adhesion but may reduce platelet 
activation and integrin αIIbβ3 inside–out signaling. In addition, 
integrin αIIbβ3 outside-in signaling is inhibited by ibrutinib, 
removing a critical source of positive feedback signaling that 
supports clot stabilization. The combined effects of ibrutinib 
on inside-out activation of integrin αIIbβ3 and outside-in signal-
ing may, therefore, account for its effects on hemostasis. The 
success of ibrutinib may stimulate the development of other 
drugs that target kinases for treatment of cancers and these 
new drugs, such as ibrutinib and dasatinib, may have off-target 
effects on hemostasis. It is therefore critical to understand how 
new kinase inhibitors affect platelet function and hemostasis. 
With improved understanding of the mechanism by which new 
kinase inhibitors such as ibrutinib cause disruption of hemo-
stasis may come with the ability to improve the safety profile 
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of future cancer drugs, predict contraindications or even inves-
tigate new potential antiplatelet drug targets.
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Ibrutinib is known to cause bleeding among patients receiving the drug but the role of platelet function deficiencies caused by ibrutinib 
downstream of GPVI are unclear. We have demonstrated that ibrutinib affects multiple platelet signaling pathways causing both a partial 
inhibition of collagen-evoked signaling during adhesion but also a strong inhibition of integrin αIIbβ3 outside-in signaling that results in the 
formation of unstable thrombi that disaggregate under shear. These defects are likely to play a role in bleeding risk among patients receiving 
ibrutinib and have implications for dosing and contraindications with drugs such as P2Y12 antagonists that we found to have an additive ef-
fect on thrombus stability. A better understanding of how new drugs that target kinases modulate platelet function and hemostasis is critical 
to improving the safety of current drug strategies and future drug development.
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